Progressive Supranuclear Palsy (PSP) - Epidemiology Forecast - 2032

DelveInsight's 'Progressive Supranuclear Palsy - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the progressive supranuclear palsy, historical and forecasted epidemiology, and the progressive supranuclear palsy trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Progressive Supranuclear Palsy Disease Understanding

Progressive supranuclear palsy, or Steele-Richardson-Olszewski and Parkinson-plus syndrome, is a rare neurodegenerative disorder and the most common atypical Parkinsonism.

It belongs to a group of diseases called tauopathies. The exact cause of progressive supranuclear palsy is unknown. However, it is believed to involve the abnormal accumulation of tau protein in certain areas of the brain, particularly the basal ganglia and brainstem, forming abnormal tangles, leading to the degeneration of brain cells.

It typically begins around the age of 60, and the symptoms gradually worsen over time. It is often characterized by the gradual deterioration of movement, balance, and coordination, dysphagia, impairment of cognitive functions, the control of eye movements, and others. The most frequent comorbidities observed in progressive supranuclear palsy patients are nervous system disorders, connective tissue diseases, eye disorders, and non-traumatic joint disorders.

Progressive supranuclear palsy encompasses several phenotype variants; Richardson's syndrome is the most common phenotype of progressive supranuclear palsy, accounting for more than 50% of cases. Other phenotypes include progressive supranuclear palsy-Parkinsonism, progressive supranuclear palsy with a predominant frontal presentation, progressive supranuclear palsy with a corticobasal syndrome, and others.

Progressive Supranuclear Palsy Diagnosis

Diagnosing progressive supranuclear palsy is challenging because its symptoms overlap with other movement disorders like Parkinson's disease, frontotemporal dementia, and corticobasal degeneration. There is no specific test for progressive supranuclear palsy, and diagnosis is usually based on the presence of characteristic symptoms, clinical examination, and ruling out other possible causes. Further, brain imaging, such as MRI, may be used to support the diagnosis by showing specific patterns of brain atrophy.

Currently, two diagnostic criteria are known as the International Parkinson and Movement Disorder Society for progressive supranuclear palsy (MDS-PSP) and National Institute of Neurological Disorders and Stroke and Society for progressive supranuclear palsy (NINDS-SPSP) are widely used by to diagnose progressive supranuclear palsy. MDS-PSP criteria include specific clinical and supportive features that help differentiate progressive supranuclear palsy from other disorders and establish an early diagnosis.

Continued in the report…..

Progressive Supranuclear Palsy Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of progressive supranuclear palsy, total diagnosed prevalent cases of progressive supranuclear palsy, gender-specific cases of progressive supranuclear palsy, phenotype-specific cases of progressive supranuclear palsy, and comorbidities-associated with progressive supranuclear palsy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Progressive Supranuclear Palsy Detailed Epidemiology Segmentation

• As per the estimates by DelveInsight, the total prevalent cases of progressive supranuclear palsy in 2022 were estimated to be approximately 80,706 cases in the 7MM. These cases are expected to increase by 2032.
• In 2022, the total diagnosed prevalent cases of progressive supranuclear palsy were estimated to be approximately 17,198 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019-2032).
• Among the 7MM, the United States accounted for approximately 33% of the total diagnosed prevalent cases of progressive supranuclear palsy in 2022, which is expected to increase further during the study period (2019-2032).
• Among the 7MM, Japan accounted for the second-highest diagnosed prevalent cases of progressive supranuclear palsy in 2022, with approximately 5,256 cases. However, these cases are anticipated to decrease by 2032.
• In 2022, there were approximately 3,655 cases of males, and approximately 2,536 cases of females suffering from progressive supranuclear palsy, respectively, in EU4 and the UK. DelveInsight estimates that these are expected to increase during the study period (2019-2032).
• In 2022, the phenotype-specific cases of progressive supranuclear palsy included progressive supranuclear palsy with Richardson's syndrome, progressive supranuclear palsy with predominant Parkinsonism, and others which were approximately 2,487, 2,331, and 933 cases, respectively, in the US. These numbers are expected to rise during the study period (2019-2032).
• The comorbidities-associated diagnosed prevalent cases of progressive supranuclear palsy were grouped into nervous system disorders, connective tissue diseases, eye disorders, and non-traumatic joint disorders in the 7MM; among the different comorbidities, nervous system disorders cases accounted for the highest, with approximately 16,613 cases, while non-traumatic joint disorders accounted for the least, with approximately 14,584 cases in 2022. The cases are expected to increase by 2032.

Scope of the Report:

• The report covers a descriptive overview of progressive supranuclear palsy, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of progressive supranuclear palsy.
• The report recognizes the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, total prevalent cases of progressive supranuclear palsy, total diagnosed prevalent cases of progressive supranuclear palsy, gender-specific cases of progressive supranuclear palsy, phenotype-specific cases of progressive supranuclear palsy, and comorbidities-associated with progressive supranuclear palsy.

Report Highlights:

• Ten years forecast of progressive supranuclear palsy
• The 7MM coverage
• Total prevalent cases of progressive supranuclear palsy
• Total diagnosed prevalent cases of progressive supranuclear palsy
• Gender-specific cases of progressive supranuclear palsy
• Phenotype-specific cases of progressive supranuclear palsy
• Comorbidities associated with progressive supranuclear palsy

Key Questions Answered

• What are the disease risk and burdens of progressive supranuclear palsy?
• What is the historical progressive supranuclear palsy patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What would be the forecasted patient pool of progressive supranuclear palsy at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with progressive supranuclear palsy?
• Out of the above-mentioned countries, which country would have the highest prevalent population of progressive supranuclear palsy during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy:

The progressive supranuclear palsy report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM progressive supranuclear palsy epidemiology forecast.
• The progressive supranuclear palsy epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The progressive supranuclear palsy epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.